Protagonist Therapeutics, Inc. - Common Stock (PTGX)

$35.87 0.78 (2.22%)

9:52 EST PTGX Stock Quote Delayed 30 Minutes

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024

By InvestorPlace Earnings Aug 6, 2024

PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

3 Growth Stocks No One Is Watching (But They Should Be)

The 3 Best Biotech Stocks to Buy in June 2024

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024

Volume:

Previous Close -

Market Cap 2.14B

PE Ratio 8.48

EPS 4.23

Volume (Avg. Vol.) 69,609

Day's Range $34.81 - $36.09

52-Week Range $24.22 - $48.89

Dividend & Yield N/A (N/A)

PTGX Stock Predictions, Articles, and Protagonist Therapeutics, Inc. - Common Stock News

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jul 13, 2023

We're starting off Thursday with a look at the biggest pre-market stock movers traders will want to keep an eye on this morning.

3 Biotech Stocks to Buy Before They Boom

By Shanthi Rexaline Jun 1, 2022

It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations.

7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years

By Nicolas Chahine, InvestorPlace Contributor May 11, 2022

Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Apr 14, 2022

The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!

3 Desirable Drug Stocks With Very Promising Pipelines

By Larry Ramer, InvestorPlace Contributor Feb 16, 2022

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

Short Squeeze Stocks: PTGX, AGC and 3 Others Experts Think Are Ready to Pop

By Chris MacDonald, InvestorPlace Contributor Oct 25, 2021

Here are five short squeeze stocks many investors are putting on their radar right now as a result of higher short interest and borrow fees.

PTGX Stock: The FDA News That Has Protagonist Therapeutics Investors Cheering Today

By William White, InvestorPlace Writer Oct 11, 2021

Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies.

Battered Protagonist Therapeutics Stock Is Primed For a Dip-Buy

By David Moadel, InvestorPlace Contributor Oct 5, 2021

When Wall Street overreacts to a news catalyst, contrarian traders can step in to take advantage of a rare opportunity now with PTGX stock.

PTGX Stock: Why Protagonist Therapeutics Is Plunging 60% Today

By Chris MacDonald, InvestorPlace Contributor Sep 17, 2021

Today, investors in Protagonist Therapeutics and PTGX stock have seen an absolutely massive decline due to an FDA hold of its clinical trial.

Protagonist Stock Jumps 58% After Re-Review of Test Results

By Chris Lau, InvestorPlace Contributor Aug 8, 2018

A re-review of the PTG-100 results undid the bad news of a discontinuation of Protagonist's clinical study. If the FDA allows the company to run Phase 2/3 studies for PTG-100, then the stock will continue its bounce higher.

Western Refining, Inc. (WNR) Signet Jewelers Ltd. (SIG) Leads 16 Activist Investor Filings

By Fintel Jun 2, 2017

13D and 13G filings are windows into activist investor activity. Today we focus on Western Digital and 15 other filings

Protagonist Therapeutics, Inc. - Common Stock (PTGX)

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024

3 Growth Stocks No One Is Watching (But They Should Be)

The 3 Best Biotech Stocks to Buy in June 2024

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Protagonist Therapeutics, Inc. - Common Stock (PTGX)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

PTGX Stock Predictions, Articles, and Protagonist Therapeutics, Inc. - Common Stock News

Subscriber Sign in